Industry Insights

  1. Unlocking Agility And Efficiency In Biomanufacturing 5/2/2025

    Discover a standardized yet flexible modular biomanufacturing system designed to accelerate timelines, improve scalability, and enhance quality while reducing costs and environmental impact.

  2. Weighing The Potential Of Humira Biosimilars In The U.S. 9/29/2020

    This two-part article series explores the factors differentiating the Humira (adalimumab) biosimilar market from that of infliximab biosimilars, which could lead to stronger uptake of these products in the U.S. In Part 1, we focus on the unique competitive dynamics within the adalimumab biosimilar market.

  3. Strategic Procurement For Emerging Pharmas & Biotechs 2/27/2023

    Emerging pharma and biotech companies depend significantly on suppliers, from initial discovery to clinical trials and regulatory approval. As a result, the sourcing and procurement function requires a strategic mindset aligned with business goals to drive an efficient purchasing process throughout the entire supply chain.

  4. Shaping A Digitally Enabled Commercialization Road Map For Your Cell/Gene Therapy Company 1/25/2024

    For cell and gene therapy companies, it is critical for commercial, marketing, and digital leaders to understand key business decisions that shape the digital backbone of your commercialization road map.

  5. How To Increase Your Medtech Growth Trajectory In Indirect Markets 4/12/2021

    In emerging as well as mature markets, we have seen the rise of smaller, more agile partners specializing on a specific sector or market segment. Since the vast majority of the growth in sales is expected to happen overseas, it is obvious that having an optimized indirect sales strategy will be instrumental to deliver results. But how do we evaluate potential channel partners? Read this article to find out!

  6. Conducting An Independent Analysis Of Drug Development Practices 2/2/2016

    Industry research shows that about 90% of all drugs in clinical development will be rejected by the FDA or will fail to reach the final stages of regulatory review for other reasons. Given the FDA’s stringent rules and standards for review of drugs, this failure rate is not completely surprising. But while we tend to associate a development program’s failure with dangerous adverse events or underwhelming efficacy data, analysis of the true risks associated with clinical research yields some surprising conclusions.    

  7. Medtech Data Analysis: Techniques to Create Business-Building Insights 4/20/2020

    Combining industry expertise with sophisticated data science methodologies offers medtechs a more precise and detailed understanding of market dynamics, enabling better business decision-making.

  8. Brexit Finalization: How Will Medical Device Compliance Change In Europe In Jan. 2021? 11/23/2020

    The UK's transition period in leaving the European Union ends on December 31, 2020. The Medicines and Healthcare products Regulatory Agency (MHRA), which regulates medical devices marketed in the UK, released new guidelines in September 2020 detailing how devices will be regulated beginning January 1, 2021, with varied compliance dates for different device classes.

  9. The Importance Of Scalability In Viral Vectors

    Diseases that lack a cure, or even treatment, may be addressed with new gene therapeutic classes. This potential has spurred new investments in the drug development and commercialization space.

  10. The Crowd Will See You Now: How Do-It-Yourself Healthcare Will Make The World A Better Place…Someday 7/23/2015

    We live in an era of convenience. We can, if we choose, grab dinner without leaving our cars, watch from the sofa as the the lawn service trims our hedges, wait for UPS to drop off our new clothes, and hang our dry cleaning outside the door for pick up. We live a life our grandparents only dreamed of.